Lycera Expands Pact With Merck | Chemical & Engineering News
Volume 91 Issue 7 | p. 27 | Concentrates
Issue Date: February 18, 2013

Lycera Expands Pact With Merck

Department: Business
Keywords: drug discovery, alliances, collaboration, immune diseases

Lycera has expanded its collaboration with Merck & Co. to develop small-molecule drugs against autoimmune diseases. In 2011, the companies began work on immune modulators targeting the retinoic acid-related orphan receptor. Under the new agreement, Merck will pay an up-front fee, provide research funding, and make up to $300 million in milestone payments. In addition, Merck will handle clinical development and commercialization of any resulting products. Lycera is a 2006 spin-off of the University of Michigan.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment